Efficacy and Safety of Dupilumab in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: Phase 3 NOTUS Trial

被引：0
|
作者：
Bhatt, S. P. [1 ]
Rabe, K. F. [2 ]
Hanania, N. A. [3 ]
Vogelmeier, C. F. [4 ]
Bafadhel, M. [5 ]
Christenson, S. A. [6 ]
Papi, A. [7 ]
Singh, D. [8 ]
Laws, E. [9 ]
Akinlade, B. [10 ]
Maloney, J. [10 ]
Lu, X. [9 ]
Bauer, D. [9 ]
Bansal, A. [10 ]
Abdulai, R. M. [11 ]
Robinson, L. B. [11 ]
机构：
[1] Univ Alabama Birmingham, Pulm Allergy & Crit Care Med, Birmingham, AL USA
[2] LungenClin Grosshansdorf GmbH, Grosshansdorf, Germany
[3] Baylor Coll Med, Houston, TX USA
[4] Univ Marburg, Marburg, Germany
[5] Kings Coll London, London, England
[6] Univ Calif San Francisco, San Francisco, CA USA
[7] Univ Ferrara, Resp Unit, Ferrara, Italy
[8] Univ Manchester, Manchester, Lancs, England
[9] Sanofi, Bridgewater, NJ USA
[10] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[11] Sanofi, Cambridge, MA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A7517
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dupilumab efficacy and safety in patients with moderate-to-severe COPD with type 2 inflammation: pooled analysis of BOREAS and NOTUS
    Bhatt, Surya
    Rabe, Klaus F.
    Hanania, Nicola
    Vogelmeier, Claus F.
    Bafadhel, Mona
    Christenson, Stephanie
    Papi, Alberto
    Singh, Dave
    Laws, Elizabeth
    Akinlade, Bolanle
    Maloney, Jennifer
    Lu, Xin
    Bauer, Deborah
    Bansal, Ashish
    Abdulai, Raolat M.
    Robinson, Lacey B.
    Bhatt, Surya
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [2] Dupilumab improves respiratory symptoms in patients with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial
    Papi, Alberto
    Bhatt, Surya P.
    Rabe, Klaus F.
    Hanania, Nicola A.
    Vogelmeier, Claus F.
    Bafadhel, Mona
    Christenson, Stephanie A.
    Singh, Dave
    Laws, Elizabeth
    Maloney, Jennifer
    Lu, Xin
    Bauer, Deborah
    Bansal, Ashish
    Robinson, Lacey B.
    Abdulai, Raolat M.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [3] Dupilumab Does Not Impact Blood Eosinophil Levels in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: From the Phase 3 Boreas Trial
    Bafadhel, M.
    Christenson, S. A.
    Hanania, N. A.
    Bhatt, S. P.
    Rabe, K. F.
    Vogelmeier, C. F.
    Papi, A.
    Singh, D.
    Laws, E.
    Nivens, C.
    Bansal, A.
    Lu, X.
    Bauer, D.
    Maloney, J.
    Robinson, L. B.
    Abdulai, R. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [4] Dupilumab improves lung function in non-exacerbators with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial
    Rabe, Klaus F.
    Vogelmeier, Claus F.
    Bhatt, Surya P.
    Hanania, Nicola A.
    Bafadhel, Mona
    Christenson, Stephanie A.
    Papi, Alberto
    Singh, Dave
    Laws, Elizabeth
    Maloney, Jennifer
    Lu, Xin
    Bauer, Deborah
    Bansal, Ashish
    Robinson, Lacey B.
    Abdulai, Raolat M.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [5] Dupilumab improves quality of life in non-exacerbators with moderate-to-severe COPD and type 2 inflammation: phase 3 BOREAS trial
    Rabe, Klaus F.
    Vogelmeier, Claus F.
    Bhatt, Surya P.
    Hanania, Nicola A.
    Bafadhel, Mona
    Christenson, Stephanie
    Papi, Alberto
    Singh, Dave
    Laws, Elizabeth
    Maloney, Jennifer
    Lu, Xin
    Bauer, Deborah
    Bansal, Ashish
    Robinson, Lacey B.
    Abdulai, Raolat M.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [6] EFFICACY AND SAFETY OF DUPILUMAB FOR COPD WITH TYPE 2 INFLAMMATION
    Bhatt, Surya P.
    Rabe, Klaus F.
    Hanania, Nicola A.
    Vogelmeier, Claus F.
    Cole, Jeremy
    Bafadhel, Mona
    Christenson, Stephanie
    Papi, Alberto
    Singh, Dave
    Laws, Elizabeth
    Mannent, Leda L. M.
    Mortensen, Eric R.
    Maloney, Jennifer
    Lu, Xin
    Bauer, Deborah J.
    Bansal, Ashish
    Robinson, Lacey
    Abdulai, Raolat
    CHEST, 2023, 164 (04) : 6531A - 6534A
  • [7] Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Eichenfield, L. F.
    Blauvelt, A.
    Rosmarin, D.
    Hussain, I.
    Davis, J. D.
    Li, M.
    Zhang, Q.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Bansal, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S104 - S104
  • [8] Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
    Zhang, Yihua
    Xu, Qiuyun
    Chen, Lihong
    Chen, Jiawen
    Zhang, Jing
    Zou, Ying
    Gong, Ting
    Ji, Chao
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [9] Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
    Castro, M.
    Corren, J.
    Pavord, I. D.
    Maspero, J.
    Wenzel, S.
    Rabe, K. F.
    Busse, W. W.
    Ford, L.
    Sher, L.
    FitzGerald, J. M.
    Katelaris, C.
    Tohda, Y.
    Zhang, B.
    Staudinger, H.
    Pirozzi, G.
    Amin, N.
    Ruddy, M.
    Akinlade, B.
    Khan, A.
    Chao, J.
    Martincova, R.
    Graham, N. M. H.
    Hamilton, J. D.
    Swanson, B. N.
    Stahl, N.
    Yancopoulos, G. D.
    Teper, A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26): : 2486 - 2496
  • [10] Dupilumab Efficacy and Safety in Children with Uncontrolled, Moderate-to-Severe Asthma: The Phase 3 VOYAGE Study
    Bacharier, L. B.
    Maspero, J. F.
    Katelaris, C. H.
    Fiocchi, A. G.
    Gagnon, R.
    de Mir, I
    Jain, N.
    Sher, L. D.
    Mao, X.
    Liu, D.
    Zhang, Y.
    Khan, A. H.
    Kapoor, U.
    Khokhar, F. A.
    Rowe, P.
    Deniz, Y.
    Ruddy, M.
    Laws, E.
    Amin, N.
    Mannent, L. P.
    Lederer, D. J.
    Hardin, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
12345